SCHEMBL6545926

SCHEMBL6545926

C=CCCOP(=O)(O)c1ccc(Oc2ccccc2)cc1CCC=C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.38
GLA P06280 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CETP P11597 1/20 0.34
MMP2 P08253 2/20 0.33
CA9 Q16790 2/20 0.33
S1PR1 P21453 2/20 0.33
TGM2 P21980 1/20 0.33
MMP8 P22894 1/20 0.33
MMP14 P50281 1/20 0.33
CA14 Q9ULX7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545094 0.82 MAPT (0.34) RAB9ASMN1; SMN2ALDH1A1KDM4EL3MBTL1
SCHEMBL6545834 0.81 ALDH1A1 (0.37) RAB9AALDH1A1KDM4EPLA2G2D
SCHEMBL6545924 0.72 GAA (0.43) GAAGLAHTTRAB9ASMN1; SMN2
SCHEMBL778515 0.71 TSHR (0.47) SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3885797 0.69 ALDH1A1 (0.40) RAB9ASMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL6545602 0.68 CA2 (0.39) GAAALDH1A1KDM4EMEN1KMT2A
SCHEMBL6545832 0.67 KDM4E (0.34) KDM4EMEN1KMT2A
SCHEMBL11568945 0.66 FFAR1 (0.53) GAAGLAHTTRAB9ASMN1; SMN2
Diphenylether SCHEMBL28670517 0.65 SMN1; SMN2 (0.47) GAAGLAHTTRAB9ASMN1; SMN2
SCHEMBL9130820 0.65 FFAR1 (0.45) HTTSMN1; SMN2ALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379533-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS Leo Pharma A/S (DK) 2004-01-14 EP disclosed
US-6605742-B2 Rheumatic diseases; antiarthritic agents; antitumor agents LEO PHARMA A/S (DK) 2003-08-12 US disclosed
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons LEO PHARMA A/S (DK) 2002-11-28 US disclosed
WO-2002083696-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS LEO PHARMA A/S (DK) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons CMA1, MMP9, CPA1 GAA 701/4885GLA 762/4885HTT 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.